Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Making drugs in space can mean growing crystals for research, processing a material in orbit and returning it for analysis, or producing a dose for astronauts. Those are different goals. The most concrete Earth-return example in the available evidence is Varda’s reported orbital processing and recovery of ritonavir crystal material—not a finished, approved medicine ready for patients.
What does “manufacturing drugs in space” actually mean?
The phrase covers several activities that should not be mistaken for one another. A crystal-growth experiment may help researchers determine a protein’s structure or investigate a formulation; it does not necessarily make a medicine. Orbital processing followed by sample return can test whether a material’s properties change in microgravity. A separate proposed approach would make small quantities of biologics in deep space for crew use, rather than manufacture products for Earth.
| Approach | Intended output | What it can establish |
|---|---|---|
| Protein-crystal growth on the ISS | Crystals for structural biology, drug discovery, formulation or potential seed-crystal applications | NASA describes hundreds of protein crystal-growth experiments on the station and possible research and formulation uses. A crystal is not, by itself, a finished medicine. |
| Orbital processing and return | A recovered material or crystal form for terrestrial characterization and development | Varda reports recovering ritonavir Form III generated in orbit and testing the stability of several ritonavir forms. That is a sample-processing result, not proof of a commercially scaled or approved drug. |
| Proposed in-space biologics production | Small quantities of biologics for astronauts on long-duration missions | NASA’s 2025 Astropharmacy abstract describes a microfluidic, spore-based concept. It is distinct from an ISS crystal-growth experiment or an Earth-market manufacturing process. |
Why might microgravity change a drug material?
On Earth, gravity drives convection in fluids and causes buoyancy and sedimentation. Microgravity suppresses those effects, changing how molecules and particles move as a material forms. Depending on the substance and process, that can influence crystal growth, particle size, shape, uniformity or solid form. It does not guarantee a better result: the outcome has to be measured for the specific molecule and method.
Crystal properties can matter because size, shape, structure and uniformity may affect pharmaceutical performance and how a product can be made. The ISS National Laboratory says more than 60% of pharmaceutical drugs are crystalline; the page reviewed does not state a publication year for that figure. The statistic is the organization’s claim, not a universal measure that establishes how many medicines would benefit from orbital processing.
#1 Best Overall
NASA describes ISS protein-crystal work as relevant to structural biology, drug discovery and possible formulation or delivery research. Better-ordered crystals may help researchers study a protein’s structure, while a formulation study may explore how a drug could be delivered. Neither outcome alone demonstrates improved patient benefit.
What has actually been demonstrated?
Protein-crystal research on the ISS
NASA says the ISS has hosted hundreds of protein crystal-growth experiments. The ISS National Laboratory’s page identifies Keytruda as one therapeutic product crystallized in space at the time the page was written, and discusses small-molecule crystallization as an opportunity. The same page says small-molecule active pharmaceutical ingredient crystals had not been generated on the station. That ISS-specific statement should not be conflated with Varda’s ritonavir work on a different orbital platform.
Rank #2
- NORTON, Easy To Read
- Ideal for a bookworm
- Compact for travelling
NASA also describes the ISS PIL-BOX as a cassette-based platform intended to produce uniform protein crystals. Such crystals can support research and may have a role as seed crystals in terrestrial manufacturing development; that is not the same as producing a finished drug in orbit.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsReturned ritonavir material
In a summary dated March 20, 2024, Varda reports that metastable ritonavir Form III generated in orbit was recovered. The company says its study tested Forms I, II and III, amorphous ritonavir, and passive controls, and reports excellent stability for the tested forms. This is evidence about recovered samples and the specific stability tests reported—not evidence of patient benefit, drug approval, cost-effectiveness, routine production or large-scale manufacturing.
Rank #3
After a sample returns, researchers need to characterize it and compare it with suitable ground controls. Varda lists methods including diffraction, thermal analysis, spectroscopy, microscopy and dissolution testing. A difference in crystal form or particle uniformity matters only if it is reproducible and translates into a useful product or process property.
A proposed pharmacy for deep-space crews
NASA’s 2025 Technical Reports Server abstract describes Astropharmacy, a concept using engineered Bacillus subtilis spores and custom microfluidic hardware to produce small quantities of biologics on demand. The abstract gives a six-month shelf-life figure for biologics even when refrigerated as context for the problem, and reports that seven small peptide drugs had been expressed in B. subtilis at that point. These are project statements in an abstract, not evidence that a flight-ready autonomous pharmacy has been deployed. The concept addresses crew supply beyond low Earth orbit; it does not establish an Earth-bound drug-manufacturing route.
Rank #4
What does it take to make an orbital process useful?
- Choose a target with a plausible gravity-sensitive step. Identify a molecule, solid form or formulation for which gravity-driven flow or settling could affect the outcome. Orbital production is not automatically preferable to ordinary terrestrial manufacturing.
- Measure the Earth process first. Establish a terrestrial baseline and identify the properties that matter, such as particle size or polymorph ratio. Varda describes using conventional or custom crystallization equipment, XRPD, DSC, TGA, particle-size analysis and real-time process monitoring in process development.
- Screen whether gravity matters. Varda describes hypergravity screening to map selected material metrics across gravity levels. These are company-described capabilities for assessing candidates, not independent proof that a flight will be economical or successful.
- Automate and control the orbital experiment. Hardware must contain the material, control relevant conditions and record what happened with limited crew involvement. NASA’s PIL-BOX is a cassette-based protein-crystallization platform; it is not the same technology as Astropharmacy’s proposed microfluidic biological production system.
- Return the sample intact enough to study. Launch, orbital conditions, reentry, recovery and handling are all part of the experimental chain. If a sample is altered or lost during return, the orbital result may be difficult to interpret.
- Characterize, reproduce and develop on Earth. Analyze the recovered material against appropriate controls, then determine whether the result can be repeated and translated into a terrestrial process. A promising sample is a starting point for development, not a substitute for it.
Why not make every drug in orbit?
The business case is selective. A target must benefit enough from a gravity-dependent process to justify automation, launch, return and downstream development. Payload volume, temperature control, process duration, recovery reliability and the ability to reproduce a useful result all affect whether an orbital experiment is worth pursuing. The available sources do not provide a standardized cost or throughput comparison, so they do not support ranking providers or claiming that orbital production is cheaper.
Free tools Windows power users keep installed
One-click scans. No signup required.
Scale-up is another hurdle. An interesting crystal or small returned batch does not show that the same result can be made reliably at manufacturing scale. Researchers would need to establish controls and specifications for the terrestrial process and demonstrate that the material’s relevant properties persist through development and production.
Best Value
Does a returned space-made drug need regulatory approval?
Successful recovery or stability testing does not establish sterility, GMP compliance, safety, efficacy, FDA approval or suitability for human use. A returned research sample is not automatically a drug product. Any product intended for patients would need the applicable quality, manufacturing and regulatory evidence for its intended use.
The FDA’s March 2023 ICH Q13 guidance addresses scientific and regulatory considerations for continuous manufacturing of drug substances and products. It is relevant background for terrestrial process control, but it is not a space-specific approval ruling and does not, by itself, resolve requirements for a particular orbital manufacturing site or returned drug.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →
